Avelumab and Merkel Cell Carcinoma: Prognosis and Treatment Options After Progression

From General Health Awareness to Occupational Risk

Public discourse on general health and science has long emphasized understanding disease progression and treatment pathways for serious conditions. This foundational awareness has equipped audiences with a baseline vocabulary for discussing oncology, including the role of immunotherapies in managing advanced cancers. Within this legacy context, the focus has been on patient outcomes and therapeutic interventions, often abstracted from the specific circumstances that lead to disease onset. Transitioning from this broad health perspective, a more targeted concern emerges when considering occupational environments where exposure to certain agents may elevate disease risk. Specifically, workers in manufacturing settings—particularly those involving chemical synthesis or material processing—may encounter substances that have been linked to rare but aggressive malignancies. One such malignancy is Merkel cell carcinoma (MCC), a neuroendocrine skin cancer with a poor prognosis in advanced stages. The therapeutic landscape for severe cases now includes Avelumab, a PD-L1 inhibitor that has shown efficacy in treating metastatic disease. This pivot from general health education to occupational exposure concern reframes the conversation: rather than focusing solely on treatment after diagnosis, it becomes critical to examine how workplace conditions might contribute to the initial development of such cancers. By bridging from legacy health literacy to this applied risk context, we can better inform prevention strategies and surveillance protocols for at-risk populations.

Avelumab in the Treatment of Metastatic Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/; https://pubmed.ncbi.nlm.nih.gov/33439294/). This approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab was the first therapeutic agent specifically approved for this indication and is approved independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is characterized by high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab and pembrolizumab, offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who become refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Prognosis and Treatment Options After Avelumab Progression

In a multicenter study of the prospective skin cancer registry ADOREG, ipilimumab plus nivolumab was evaluated in avelumab-refractory MCC patients, with three out of five patients responding according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC further supports this approach (https://pubmed.ncbi.nlm.nih.gov/35877101/). Checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case describes hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case highlights the potential for avelumab to trigger immune-mediated conditions beyond typical irAEs, which may complicate prognosis and require careful monitoring. The adequacy of warnings regarding avelumab and MCC is supported by clinical trial data and post-marketing reports, but the risk of progression remains significant. For affected patients, prognosis-related considerations include the high likelihood of progression despite initial response, as approximately 50% of patients progress on immune checkpoint inhibitors (https://pubmed.ncbi.nlm.nih.gov/35877101/). The timeline between exposure to avelumab and documented harm can vary. In the JAVELIN Merkel 200 trial, objective responses were observed in about one-third of patients, indicating that some patients may experience benefit within weeks to months of starting treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, for those who progress, the timeline to documented harm—such as disease progression or immune-related adverse events—can occur during treatment or after discontinuation. The case of sarcoidosis reactivation occurred during avelumab therapy, with hypercalcemia managed successfully (https://pubmed.ncbi.nlm.nih.gov/31543781/). For avelumab-refractory patients, subsequent treatment with ipilimumab plus nivolumab may offer a salvage option, but data are limited to small retrospective series (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/35877101/). In summary, avelumab represents a significant advancement in the treatment of metastatic MCC, but its use is associated with a substantial risk of progression and immune-related adverse events. The prognosis for patients who progress on avelumab remains poor, though combination immunotherapy with ipilimumab plus nivolumab may provide benefit in some cases. Clinicians should monitor for both disease progression and immune-related toxicities, with awareness that the timeline for harm can be unpredictable.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Avelumab and how does it work for Merkel cell carcinoma?

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved for the treatment of metastatic Merkel cell carcinoma (MCC) based on the JAVELIN Merkel 200 trial, which showed objective responses in about one-third of patients (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What are the treatment options for Merkel cell carcinoma that progresses after Avelumab?

For patients who become refractory to avelumab, efficient and safe treatment options are limited (https://pubmed.ncbi.nlm.nih.gov/33439294/). However, combination immunotherapy with ipilimumab plus nivolumab has shown promise in small studies, with three out of five patients responding in one multicenter study (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/35877101/).

What are the risks and side effects of Avelumab treatment?

Checkpoint inhibitors like avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case involved hypercalcemia from sarcoidosis reactivation, which was managed with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781/). Additionally, approximately 50% of patients with advanced MCC progress on immune checkpoint inhibitors (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.